Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study

Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, mitsumasa kishimoto⁴, Ruben Queiro⁵, Ennio Lubrano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Enrique R. Soriano¹⁰, Proton Rahman¹¹, Frank Behrens¹² and Stefan Siebert¹³, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Kyorin University School of Medicine, Tokyo, Japan, ⁵Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ⁶Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹²Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹³University of Glasgow, Glasgow, United Kingdom

Meeting: ACR Convergence 2025

Keywords: Biologicals, Interleukins, Psoriatic arthritis

Session Information

Date: Sunday, October 26, 2025

Title: (0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Randomized controlled trials have demonstrated the efficacy of IL-23 inhibitors (i) and IL-17i in PsA; however, real-world data on their effectiveness in heterogeneous patient (pt) subgroups in routine care are limited. Some subgroups, such as older, obese, or biologic-experienced pts, are of particular interest as pts in these groups report worse treatment outcomes.1 The objective of the current analysis was to assess the 6-month persistence and effectiveness of guselkumab (GUS) and IL-17i across these subgroups of interest.

Methods: PsABIOnd (NCT05049798) is a global (20 countries) observational study in pts with PsA starting GUS or IL‑17i as 1st-to-4th line of biologic therapy per their standard of care.2 Here, the full population of the PsABIOnd study over 6 months of follow up was analyzed. Analyses were performed according to initial treatment group allocation in the overall population and in specific subgroups defined by baseline (BL) age, sex, BMI categories, and prior biologic use. Persistence on treatment (i.e., no stop/switch) over 6 months was assessed via the Kaplan-Meier estimator function. Propensity score (PS) analysis was used to evaluate hazard ratio (HR) of GUS vs IL-17i stop/switch prior to the 6-month visit, adjusting for BL variable imbalances across cohorts. Effectiveness was descriptively assessed using rates and means at BL and 6 months of the following measures: swollen (SJC66) and tender (TJC68) joint counts, clinical Disease Activity Index for PsA (cDAPSA)-based low disease activity (LDA)/remission (REM; ≤13), the Leeds Enthesitis Index (LEI; 0-6), psoriasis body surface area (BSA)< 3%, Dermatology Life Quality Index (DLQI), and number of nails affected by psoriatic disease (0-20). Dactylitis was not assessed due to the low prevalence of dactylitis at BL

Results: Of the 1134 pts analyzed, 555 and 579 pts received GUS or IL-17i, respectively, as their initial treatment. At BL, the GUS/IL-17i cohorts were generally well balanced across subgroups of interest: 83.4%/81.3% were < 65 years of age; 60.4%/59.2% were female; 48.0%/43.4% had BMI≥30 kg/m2; and 63.4%/62.3% had previously received ≥1 targeted therapy. Persistence on treatment up to 6 months was high in both cohorts, with 526/555 (94.8%) GUS and 539/579 (93.1%) IL-17i pts remaining on their initial treatment line at the 6-month visit (PS-adjusted HR of GUS vs IL-17i stop/switch [95% confidence interval]: 0.93 [0.75-1.16]; Fig 1). Persistence on GUS and IL-17i was also comparable in the different pt subgroups (data not shown). Across pt subgroups of interest, similar improvements in joint symptoms (SJC66; TJC68; cDAPSA LDA/REM; Fig 2A), enthesitis (LEI; Fig 2B), skin involvement (BSA< 3%; Fig 2C; DLQI), and psoriatic nail disease were observed with GUS and IL-17i at the 6-month visit.

Conclusion: Treatment with GUS or IL-17i resulted in comparable treatment persistence and effectiveness, regardless of age, sex, BMI, or treatment history, through 6 months. These results support the real-world effectiveness of GUS and IL-17i across PsA subpopulationsReferences1. Haddad. Semin Arthritis Rheum. 2025;1527372. Siebert. Rheumatol Ther. 2023;10:489

Disclosures: L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, BMS, 2, Celltrion, 2, Eli Lilly, 2, 5, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, UCB, 2, 5; M. Sharaf: Johnson & Johnson, 3, 11; X. Baraliakos: AbbVie, 2, 5, 6, 12, Paid Instructor, Advanz, 2, 6, 12, Paid instructor, Alexion, 2, 6, 12, Paid instructor, Alphasigma, 2, 6, 12, Paid instructor, Amgen, 2, 6, 12, Paid instructor, BMS, 2, 6, 12, Paid instructor, Celgene, 6, Celltrion, 2, 5, 6, 12, Paid instructor, Cesas, 2, 6, 12, Paid instructor, Chugai, 2, 6, Clarivate, 6, 12, Paid instructor, Galapagos, 2, 6, 12, Paid instructor, J&J, 2, 6, 12, Paid instructor, Janssen, 5, Lilly, 2, 6, 12, Paid instructor, Merck, 6, MoonLake, 2, 5, 6, 12, Paid instructor, MSD, 2, Novartis, 2, 5, 6, 12, Paid instructor, Peervoice, 2, 6, 12, Paid instructor, Pfizer, 2, 6, 12, Paid instructor, Roche, 2, 6, 12, Paid instructor, Sandoz, 2, 6, 12, Paid instructor, Springer, 2, 6, 12, Paid instructor, Stada, 2, 6, 12, Paid instructor, Takeda, 2, 6, 12, Paid instructor, UCB, 2, 6, 12, Paid instructor, Zuellig, 2, 6, 12, Paid instructor; m. kishimoto: AbbVie, 2, 6, Amgen, 2, 6, Asahi-Kasei Pharma, 2, 6, Astellas, 2, 6, Ayumi, 2, 6, BMS, 2, 6, Celgene, 2, 6, Chugai, 2, 6, Daiichi-Sankyo, 2, 6, Eisai, 2, 6, Eli Lilly, 2, 6, Gilead, 2, 6, Johnson & Johnson, 2, 6, Kyowa Kirin, 2, 6, Novartis, 2, 6, Ono Pharma, 2, 6, Takeda, 2, 6, Tanabe-Mitsubishi, 2, 6, UCB, 2, 6; R. Queiro: AbbVie, 2, 5, 6, Amgen, 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6, Johnson & Johnson, 2, 5, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6; E. Lubrano: AbbVie, 6, Amgen, 6, Eli Lilly, 6, GlaxoSmithKlein, 6, Johnson & Johnson, 6, Novartis, 6, UCB, 6; E. Rampakakis: Johnson & Johnson, 2, JSS Medical Research, 3; L. Köleséri: IQVIA, 3, Johnson & Johnson, 2; K. Lozenski: BMS, 11, Johnson & Johnson, 3, 11; E. Soriano: AbbVie, 5, 6, BMS, 5, 6, Eli Lilly, 5, 6, GSK, 5, 6, J&J, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Raffo, 5, 6, UCB, 5, 6; P. Rahman: Abbott, 2, AbbVie, 2, Amgen, 2, BMS, 2, Celgene, 2, Eli Lilly, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, UCB, 2; F. Behrens: AbbVie, 2, 6, BMS, 2, 6, Boehringer Ingelheim, 2, 6, Celgene, 2, 5, 6, Chugai, 2, 5, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Genzyme, 2, 6, Gilead, 2, 6, Johnson & Johnson, 2, 5, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Sanofi, 2, 6, UCB, 2, 6; S. Siebert: AbbVie, 6, Amgen, 6, AstraZeneca, 6, BMS, 5, Boehringer-Ingelheim, 5, Eli Lilly, 5, GlaxoSmithKlein, 5, Johnson & Johnson, 5, 6, Novartis, 6, Pfizer, 6, Syncona, 6, Teijin Pharma, 6, UCB, 5, 6.

To cite this abstract in AMA style:

Gossec L, Sharaf M, Baraliakos X, kishimoto m, Queiro R, Lubrano E, Rampakakis E, Köleséri L, Lozenski K, Soriano E, Rahman P, Behrens F, Siebert S. Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/persistence-and-effectiveness-across-psa-patient-subgroups-with-guselkumab-and-il-17-inhibitors-6-month-results-of-the-psabiond-observational-study/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-and-effectiveness-across-psa-patient-subgroups-with-guselkumab-and-il-17-inhibitors-6-month-results-of-the-psabiond-observational-study/